Bicycle Therapeutics plc Restricted Cash and Cash Equivalents
Bicycle Therapeutics plc (BCYC) had Restricted Cash and Cash Equivalents of $547.00 thousand as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-10-30
- 2025-09-30: Restricted Cash and Cash Equivalents $547.00K.
- 2025-06-30: Restricted Cash and Cash Equivalents $547.00K.
- 2024-12-31: Restricted Cash and Cash Equivalents $500.00K.
- 2024-09-30: Restricted Cash and Cash Equivalents $547.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2025-09-30 | $547.00K 10-Q · filed 2025-10-30 |
| 2025-06-30 | $547.00K 10-Q · filed 2025-08-08 |
| 2024-12-31 | $500.00K 10-Q · filed 2025-10-30 |
| 2024-09-30 | $547.00K 10-Q · filed 2025-10-30 |
| 2024-06-30 | $547.00K 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |